KEPI Inhibitors

KEPI (Kinase-Enhanced Protein Phosphatase 1 Inhibitor) inhibitors function through a multitude of mechanisms. Staurosporine and Go 6983 directly target protein kinase C (PKC), an enzyme known to phosphorylate KEPI, thereby suppressing its functional roles such as protein-protein interactions. PD98059 takes a different approach by targeting the upstream MEK in the ERK pathway, a signaling cascade implicated in KEPI regulation. This dampens ERK activation and subsequently influences KEPI. SP600125 inhibits JNK, a component of the MAPK pathway, effectively suppressing JNK-mediated activation of KEPI. SB203580 inhibits p38 MAPK, leading to reduced phosphorylation of KEPI by this kinase, whereas LY294002 disrupts the PI3K/Akt signaling to indirectly inhibit KEPI activity.

Similarly, H-89 and KN-93 act upon protein kinases but focus on PKA and CaMKII, respectively. H-89 suppresses PKA phosphorylation of KEPI, inhibiting its activity. KN-93 intervenes by halting CaMKII-dependent phosphorylation of KEPI. Wortmannin, like LY294002, disrupts PI3K/Akt signaling, but targets Akt phosphorylation more specifically. PP2 targets Src kinases, which have been observed to phosphorylate KEPI; by inhibiting Src activation, KEPI phosphorylation is suppressed. Rapamycin inhibits mTORC1, which can regulate KEPI indirectly through p70 S6 kinase. Finally, Chelerythrine is another broad PKC inhibitor, limiting PKC-mediated phosphorylation and thus the protein-protein interactions involving KEPI.